Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M90,770Revenue (TTM) $M30,390Net Margin (%)44.4Altman Z-Score3.6
Enterprise Value $M58,390EPS (TTM) $9.9Operating Margin %58.0Piotroski F-Score5
P/E(ttm)7.2Beneish M-Score-2.6Pre-tax Margin (%)56.2Higher ROA y-yN
Price/Book4.710-y EBITDA Growth Rate %--Quick Ratio4.0Cash flow > EarningsN
Price/Sales3.25-y EBITDA Growth Rate %55.0Current Ratio4.2Lower Leverage y-yY
Price/Free Cash Flow7.8y-y EBITDA Growth Rate %-11.6ROA % (ttm)25.6Higher Current Ratio y-yY
Dividend Yield %2.7PEG0.1ROE % (ttm)80.3Less Shares Outstanding y-yY
Payout Ratio %17.0Shares Outstanding M1,310ROIC % (ttm)67.7Gross Margin Increase y-yN

Gurus Latest Trades with GILD

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

GILD is held by these investors:

GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MARTIN JOHN CExecutive Chairman 2017-02-01Sell73,333$72.57-4.85view
MARTIN JOHN CExecutive Chairman 2017-01-03Sell73,337$73.59-6.17view
MARTIN JOHN CExecutive Chairman 2016-12-01Sell100,000$73.33-5.84view
MADIGAN JOHN WDirector 2016-11-18Sell105,000$74.86-7.76view
Alton Gregg HEVP Comm&Acs ALA, Corp&Med Aff 2016-11-09Sell10,000$79-12.59view
MARTIN JOHN CExecutive Chairman 2016-11-01Sell100,000$73.76-6.39view
MARTIN JOHN CExecutive Chairman 2016-10-03Sell100,000$77.63-11.05view
Alton Gregg HEVP Comm&Acs ALA, Corp&Med Aff 2016-09-22Sell5,000$81.84-15.63view
MILLIGAN JOHN FPresident and CEO 2016-09-06Sell70,000$77.74-11.18view
MARTIN JOHN CExecutive Chairman 2016-09-01Sell100,000$77.48-10.88view

Quarterly/Annual Reports about GILD:

News about GILD:

Articles On GuruFocus.com
10 Undervalued Stocks for the Enterprising Investor Feb 16 2017 
Under the Microscope: Gilead's Recent Dividend Increase Feb 15 2017 
Consider Gilead Sciences Feb 14 2017 
Gilead Sciences, Fossil Reach 3-Year Low Prices Feb 12 2017 
How BioVie, Conatus and PhaseRX Tackle Liver Diseases Feb 08 2017 
10 Low PE Stock Picks for the Enterprising Investor Feb 04 2017 
5 Companies Near 52-Week Lows Feb 03 2017 
John Paulson's Bargain Stock Jan 30 2017 
10 Undervalued Stocks for the Enterprising Investor Jan 26 2017 
6 Stocks Trading Below Peter Lynch Value Jan 26 2017 

More From Other Websites
Did Gilead's new tool for speeding drug approval come at bargain-basement price? Feb 21 2017
[$$] Gilead Goes to the Head of the Line Feb 21 2017
Sarepta Sells Priority Review Voucher for $125M Feb 21 2017
Sarepta sells FDA review voucher for $125M, but analyst questions price Feb 21 2017
Gilead Sells Anti-Addiction Drug to Amygdala Feb 20 2017
Your Burning Biotech Questions Answered Feb 20 2017
Gilead Receives Approval in Canada for ODEFSEY™ for the Treatment of HIV-1 Infection Feb 16 2017
Cramer fires back at naysayers: Here's your proof that th... Feb 15 2017
Proof the rally is real Feb 15 2017
Under the Microscope: Gilead's Recent Dividend Increase Feb 15 2017
Bristol-Myers: Don't Bet on a Pfizer Acquisition Feb 15 2017
Gilead’s HIV Drug Reports Positive Trial Data Feb 15 2017
Gilead Sciences (GILD) Value Trap Feb 15 2017
Gilead Sciences: Its Game to Lose? Feb 15 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)